Supernus Pharma (SUPN) Tops Q3 EPS by 11c; Lowers FY Revenue Outlook

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.52, $0.11 better than the analyst estimate of $0.41. Revenue for the quarter came in at $103 million versus the consensus estimate of $100.61 million.

GUIDANCE:

Supernus Pharma sees FY2018 revenue of $388-395 million, versus prior of $385-$400 and the consensus of $398.7 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• Is Treasury selloff a major issue for stock market bulls?